Starpharma Pty Ltd: Clinical Trials

3 completed. 3 Phase 2, 1 Phase 1.

By phase and status

Phase	Trials	Status
Phase 2	3	Completed 3
Phase 1	1	Completed 1

Follow Starpharma Pty Ltd: new trials by email

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Dose-ranging Study of SPL7013 Gel for the Prevention of Bacterial Vaginosis (BV) 1% SPL7013 Gel, 3% SPL7013 Gel, placebo gel - Recurrent Bacterial Vaginosis (BV)	Phase 2	Completed	Starpharma Pty Ltd	205	2011-08-01	2013-11-20
Dose Ranging Study of SPL7013 Gel for Treatment of Bacterial Vaginosis (BV) 0.5% SPL7013 Gel, 1.0% SPL7013 Gel, 3.0% SPL7013 Gel - Bacterial Vaginosis	Phase 2	Completed	Starpharma Pty Ltd	132	2010-08-01	2019-06-06
Retention and Duration of Activity of SPL7013 (VivaGel®) After Vaginal Dosing. 3% SPL7013 Gel (VivaGel) - HIV Infections, HSV-2 Genital Herpes	Phase 1 / Phase 2	Completed	Starpharma Pty Ltd	12	2008-08-01	2018-10-30

Conditions studied

Vaginosis, Bacterial (2)  ·  HIV Infections (1)  ·  Recurrence (1)

Interventions

astodrimer (1)

Countries

Australia (1)  ·  United States (1)

Top investigators

Anne Macek, MD (1)  ·  Jeremy Paull, PhD (1)